Publications by authors named "Yuji Shimura"

Claim this Profile
I
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum.
Yusuke Okayama, Teruhito Takakuwa, Yuji Shimura, Kazunori Imada, Satoru Kosugi

Hematology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Immunophenotypically diverse immature patterns, including variable TdT expression, in aggressive B-cell lymphomas and leukemia with rearrangement.
Daishi Kato, Takahiro Fujino, Reiko Isa, Haruya Okamoto, Taku Tsukamoto, Yuji Shimura

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated by Paraneoplastic Encephalitis.
Yu Inoue, Taku Tsukamoto, Kentaro Mizuhara, Chika Maekura, Takahisa Nakamura, Yuji Shimura

Intern Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.
Akio Onishi, Aya Miyagawa-Hayashino, Haruya Okamoto, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.
Takahiro Fujino, Haruya Okamoto, Daichi Nishiyama, Hiroki Hayata, Nana Sasaki, Kazuho Shimura, Yuji Shimura

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.
Akihiro Miyashita, Taichi Murao, Yuji Shimura, Haruya Okamoto, Hiroaki Nagata

Cureus· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)].
Eri Kawata, Takahiro Fujino, Tsutomu Kobayashi, Haruya Okamoto, Taku Tsukamoto, Yuji Shimura

Rinsho Ketsueki· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.
Hiroaki Nagata, Taku Tsukamoto, Tsutomu Kobayashi, Ryoichi Takahashi, Akira Okano, Yuji Shimura

Int J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma.
Tomoyasu Jo, Kyoko Yoshihara, Masaki Ri, Nobuhiro Tsukada, Naoya Mimura, Yuji Shimura

Blood Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities.
Haruya Okamoto, Shinsuke Mizutani, Taku Tsukamoto, Yoko Katsuragawa-Taminishi, Yuka Kawaji-Kanayama, Yuji Shimura

Leukemia· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Naokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura

Ann Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.
Yutaka Shimazu, Junya Kanda, Teruhito Takakuwa, Yoshiyuki Onda, Kentaro Fukushima, Yuji Shimura

Ann Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia.
Junya Kuroda, Mio Yamamoto, Hisao Nagoshi, Tsutomu Kobayashi, Nana Sasaki, Yuji Shimura

Mol Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Daisuke Ide, Takahiro Fujino, Tsutomu Kobayashi, Aya Egashira, Akihiro Miyashita, Yuji Shimura

Int J Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of trisomy 9 with mixed-field ABO blood type.
Sena Fujii, Yuji Shimura, Keiichi Shigehara, Yuji Sasada, Tohru Inaba

Blood Transfus· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Autopsy Case of Severe COVID-19 Pneumonia Complicated by Intrapulmonary Thrombosis in Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis.
Yoshinori Harada, Masahiro Makino, Ryuta Nakao, Yuji Shimura, Takehiro Ogata

Cureus· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura

Cancer Immunol Immunother· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Good's Syndrome With Pure Red Cell Aplasia and Subclinical Myasthenia Gravis: A Case Report and Review of Literature.
Wakana Hashiro, Akihiro Miyashita, Yuka Kawaji-Kanayama, Haruya Okamoto, Takahiro Fujino, Yuji Shimura

Cureus· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Yuka Kawaji-Kanayama, Taku Tsukamoto, Masakazu Nakano, Yuichi Tokuda, Hiroaki Nagata, Yuji Shimura

Cancer Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.
Yu Inoue, Haruya Okamoto, Akihiro Miyashita, Yuka Kawaji-Kanayama, Shotaro Chinen, Yuji Shimura

Oncol Lett· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
Akio Onishi, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Reiko Isa, Takahiro Fujino, Kazuho Shimura, Yuji Shimura

Int J Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma.
Yui Niiyama-Uchibori, Haruya Okamoto, Akihiro Miyashita, Kentaro Mizuhara, Yuka Kanayama-Kawaji, Yuji Shimura

Hematol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
Yoko Katsuragawa-Taminishi, Shinsuke Mizutani, Yuka Kawaji-Kanayama, Akio Onishi, Haruya Okamoto, Yuji Shimura

Cancer Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Yuji Shimura

Leuk Res Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Immune suppressive cells in the tumor microenvironment of multiple myeloma].
Yuji Shimura

Rinsho Ketsueki· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis